BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.

On February 26, 2019, the Company andEndoGlobal Ventures, a Bermuda unlimited liability company (“EndoGlobal Ventures”) entered into the Second Amendment to Second Amended and Restated Development and License Agreement (the “Second Amendment”) to amend certain provisions of the Second Amended and Restated Development and License Agreement, by and between the Company and Auxilium Pharmaceuticals, Inc. (“Auxilium”), dated as of August 31, 2011 (the “License Agreement”), which was filed with the Securities and Exchange Commission (the “SEC”) on September 1, 2011 as Exhibit 10.1 to a Current Report on Form 8-K. Auxilium subsequently assigned the License Agreement to Auxilium Bermuda ULC.EndoInternational plc (“Endo”) acquired Auxilium on January 29, 2015, and changed the name of Auxilium Bermuda ULC, now an affiliate ofEndo, toEndoGlobal Ventures.

The Second Amendment has an effective date of January 1, 2019. to the terms of the Second Amendment, the Company has consented to the assignment of the License Agreementby EndoGlobal Ventures to Endo Global Aesthetics Limited, an Irish private company and an affiliate of Endo Global Ventures that is indirectly wholly-owned by Endo. In addition, the Second Amendment amends certain provisions of the License Agreement to require Endo to provide timely estimates of royalties to assist the Company in complying with its financial reporting obligations.

The foregoing is a summary description of certain terms of the Second Amendment and, therefore, does not purport to be complete. This description is qualified in its entirety by the text of the Second Amendment, which is attached as Exhibit 10.1 to this Current Report on Form 8-K. All readers are encouraged to read the entire text of the Second Amendment.

(d)

BIOSPECIFICS TECHNOLOGIES CORP Exhibit
EX-10.1 2 exhibit10-1.htm EXHIBIT 10.1 Biospecifics Technologies Corp.: Exhibit 10-1 – Filed by newsfilecorp.com EXECUTION VERSION SECOND AMENDMENT TOSECOND AMENDED AND RESTATED DEVELOPMENTAND LICENSE AGREEMENT This SECOND AMENDMENT TO SECOND AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT dated February 26,…
To view the full exhibit click here

About BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC)

BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. Its injectable collagenases are marketed for indications, such as Dupuytren’s contracture and Peyronie’s disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren’s contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.